ATAI Life Sciences N.V (NASDAQ:ATAI) has a beta value of 1.48 and has seen 2.79 million shares traded in the recent trading session. The company, currently valued at $475.80M, closed the recent trade at $2.38 per share which meant it gained $0.07 on the day or 2.81% during that session. The ATAI stock price is -7.98% off its 52-week high price of $2.57 and 56.72% above the 52-week low of $1.03. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.12 million shares traded. The 3-month trading volume is 1.88 million shares.
The consensus among analysts is that ATAI Life Sciences N.V (ATAI) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.11.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Over the past 30 days, the shares of ATAI Life Sciences N.V (NASDAQ:ATAI) have changed 61.56%. Short interest in the company has seen 12.79 million shares shorted with days to cover at 9.5.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 52.4% from the levels at last check today.. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -110.08% off the targeted high while a plunge would see the stock gain -110.08% from the levels at last check today..
ATAI Life Sciences N.V (ATAI) estimates and forecasts
The company’s shares have gained 40.53% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 327.49%.
Year-ago sales stood 273k and 40k respectively for this quarter and the next, and analysts expect sales will shrink by -100.00% for the current quarter and 327.49% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.62% over the past 5 years. Earnings growth for 2025 is a modest 39.13% while over the next 5 years, the company’s earnings are expected to increase by 29.20%.
ATAI Dividends
ATAI Life Sciences N.V is expected to release its next earnings report on 2025-May-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
Insiders own 8.26% of the company shares, while shares held by institutions stand at 32.69% with a share float percentage of 35.63%. Investors are also buoyed by the number of investors in a company, with ATAI Life Sciences N.V having a total of 106.0 institutions that hold shares in the company. The top two institutional holders are WALLEYE CAPITAL LLC with over 2.76 million shares worth more than $3.67 million. As of 2024-06-30, WALLEYE CAPITAL LLC held 1.7226% of shares outstanding.
The other major institutional holder is MORGAN STANLEY, with the holding of over 2.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.62 million and represent 1.6952% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are MORGAN STANLEY INSTITUTIONAL FUND INC-Inception Portfolio and AdvisorShares Trust-AdvisorShares Psychedelics ETF . As of Mar 31, 2025 , the former fund manager holds about 0.26% shares in the company for having 511.99 shares of worth $1.25 million while later fund manager owns 415.76 shares of worth $1.02 million as of Apr 30, 2025 , which makes it owner of about 0.21% of company’s outstanding stock.
